0800 292 2014 info@medira.co.uk

Neuskin®-F

Neuskin®-F is an effective epidermal substitute that supports epidermal cell attachment and migration 1,2,3,4,5

Indications

  • Donor sites or non-healing donor sites
  • Superficial to partial thickness burns
  • Abrasions and skin tears
  • Venous stasis leg ulcers

Neuskin®-F is a Type I collagen film membrane

  • provides a biodegradable collagen substrate for migrating keratinocytes 5
  • a natural matrix for cellular growth and vascularisation 3, 5
  • Fish collagen source reducing risks associated with mammalian collagen dressings
  • Quick and firm adherence to wound bed
  • Transparent membrane enables wound visualisation
  • Adaptable to all body areas
  • Provides immediate pain relief 3 for patients

 

 

 

 

Neuskin-F application on donor site Showing healing in 7 days

 

 

 

 

“I am extremely impressed with results to date. My first patient had extensive non-healing donor sites that showed epithelialisation in 7 days after using Neuskin-F.” GL, Plastics Clinical Nurse Specialist, London

Neuskin®-F is a collagen dressing derived from Piscean sources

  • Biocompatible as per EN ISO 10093 standards
  • Non-toxic, non-allergenic, non-immunogenic, non-pyrogenic

References

  1. Horch RE, Stark GB. Comparison of the effect of a collagen dressing and polyurethane dressing on healing of split thickness skin graft donor sites. Scand J Plast Reconst Surg Hand Surg 1998; 32 (4) : 407-13.
  2. Kilinc H, Sensoz O, Ozdemir R, Unlu RE, Baran C. Which dressing for split thickness skin graft donor site? Ann Plast Surg 2001; 46 (4) : 409-14.
  3. Parks WC. The production, role, and regulation of matrix metalloproteinases in the healing epidermis. WOUNDS. 1995;7(Suppl A):23–37.
  4. Ponten B, Nordgaard JO. The Use of Collagen Film as a Dressing for Donor Areas in split skin grafting. Scand J Plast Reconstr Surg 1976; 10 : 237-40.
  5. 8 Scharffetter-Kochanek K, Klein CE, Heinen G, et al. Migration of human keratinocyte cell line (HaCaT) to interstitial collagen Type I is mediated by the alpha 2 beta 1-integrin receptor. J Invest Dermatol. 1992;98(1):3–11.